Category: Artificial Intelligence

Explore our library of blogs, insights, research papers, and more information on compliance in the life sciences industry.

Imagine yourself focusing hard, while being mindful of a lot of things simultaneously taking place in many different directions. Lots of sensory and background information flowing at you, which could overwhelm you had you been a newcomer. The task looks operational, but it has high-risk, long-term consequences. It is absolutely necessary to get it right […]

Pharmaceutical companies do not want to keep doctors away. But even if they did, it would be easier (and riskier) than taking an apple a day. A lot riskier. Tiny typos can have huge consequences. Without meaning to, and often under pressure to meet submission deadlines, compliance/transparency professionals can make errors that increase their workload […]

Regulator visitors to this blog will know how important it is for qordata to get facts about pharmaceutical spend data right. We would go so far as to say that protecting the sanctity, validity, and relevance of this data has a sacred status with us. But before data can be all this, it needs to […]

People seeking to spend data on a specific physician will be searching through more than 600,000 physicians and/or going through 1,100 teaching hospital records with the latest update CMS makes in its Open Payments Database. At qordata, we have employed our data engineering chops to make your life just that much easier. This is the […]

CMS open payments reporting solution, qordata’s foremost solution for pharmaceutical spend analytics, helps drug and device manufacturers gain visibility into their spend data. With the publication of 2016 records by CMS on 30th June 2017, qordata has been amongst the first to share the industry’s most incisive insights in this blog. Data from 2016’s records […]

In our previous post on Dr. Klaus Geltsetzer’s webinar presentation, How to “Determine the Relationships of Different Global Disclosure Requirements,” we described how Germany’s consent rates tell an interesting story, depending on how they’re calculated. We’re resuming the debate on Germany’s position in the pharmaceutical transparency space. This time, we discuss industry-led, private-sector synergy. Or […]